Textbook of Personalized Medicine - Second Edition [2015]

717

asthma , 515
CF , 548
CFS , 455
colorectal cancer , 338
GxE interactions , 23
Huntington disease , 424
lung function and ancestry , 511
rheumatoid arthritis , 554
Environment-wide association studies
(EWAS) , 182
Enzymatic mutation detection (EMD) , 39–40
Enzyme replacement therapy (ERT) , 537,
538, 544
Epidermal growth factor receptor (EGFR) ,
223, 225, 227, 299, 347
Epigenomics , 183–184, 412–413
Epilepsy
antiepileptic drugs , 425, 429
biomarkers , 426–427
drug resistance in , 431–433
future prospects , 433–435
genetics/genomics of , 427–428
pharmacogenetics , 431
pharmacogenomics , 429–430
Epithelial ovarian carcinoma (EOC) , 318, 319
Epizyme Inc , 259
Epstein-Barr virus (EBV) infection , 248
Esophageal cancer , 337
Estramustine phosphate (EMP) , 364
Estrogen receptor 1 gene (ESR1) , 581
Ethics
gene patents , 663–664
genetic information
direct-to-consumer genetic services ,
657–658
genotype-specifi c clinical trials , 659–660
GINA , 659
privacy issues , 658–659
whole genome analysis , 656–657
pharmacogenetics , 655–656
race and , 660–663
social issues , 660
EuroCHAVI project , 390
European Personalized Medicine Diagnostics
Association (EPEMED) ,
647–648
European Union (EU), personalized medicine
2004 consumer survey , 647
developing countries , 650–651
EPEMED , 647–648
Germany , 649
INCPM , 650
UK national health service and medical
genetics , 648–649

Evaluation of Genomic Applications in

Practice and Prevention (EGAPP) ,

608–609, 614

Evidence-based medicine , 21

Evidence-Based Practice Centers (EPCs) , 606

Extracellular domain (ECD) , 220

F

Factor V Leiden mutation , 502–503

FANG™ vaccine , 242, 252

FDA. See Food and drug administration (FDA)

Female sexual dysfunction (FSD) , 571–572

Fiber array scanning technology (FAST) , 298

Ficlatuzumab , 348

FISH-on-chip technology , 56–57

Fixed paraffi n-embedded tissues (FPET) , 225

Fluorescence activated cell sorting (FACS)

techniques , 161

Fluorescence in situ hybridization (FISH) ,

208, 531

5-Fluoro-2-deoxyuridine monophosphate

(5-FdUMP) , 267–268

Follicular lymphoma , 242–243, 336

Food and drug administration (FDA)

biomarkers validation , 669, 671

Clinical Proteomics Program , 613

companion diagnostics and therapies ,

674–676

multivariate index assays , 672–674

and NIH , 610

pharmacogenetics , 666

and pharmacogenomics

data submissions , 667–668

drug-dosing , 669

drug labels , 668–670

European drug regulators , 668

and predictive medicine , 671–672

product development and use , 666

Frequentist approach , 95–96, 593

Fungal infections , 405

G

Gabapentin , 595

Gastric cancer , 337–338

Gastrointestinal cancer

colorectal cancer ( see Colorectal

cancer (CRC))

esophageal cancer , 337

gastric cancer , 337–338

Gastrointestinal disorders

infl ammatory bowel disease , 566–567

lactose intolerance , 568

Index